NEWS
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024
Zevra Therapeutics (NASDAQ: ZVRA) announced that top-line data from its Phase 2 clinical trial of KP1077 for idiopathic hypersomnia (IH) will be presented at Sleep Europe 2024. The trial (NCT05668754) was a placebo-controlled, double-blind, randomized withdrawal study evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in IH patients. Dr. Rene Braeckman, Zevra's Senior VP of Clinical Development, will present the findings, which demonstrate clinically meaningful benefits for key IH symptoms. The data will provide important information for designing a Phase 3 study. Presentations will include an oral session on September 27 and a poster session on September 26 at the 27th Congress of the European Sleep Research Society in Seville, Spain.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment